Pipeline

Intelligent Chemistry, Better Medicines for Complex Diseases

Decoration

Delivering potent once-daily oral medicines designed for long-term safety and earlier intervention

Our pipeline is the product of our uniquely diverse chemistry, the power of our AI platform, and the deep expertise of our drug developers. We discover novel small molecule solutions for validated disease targets that offer patients alternatives to biologics as well as combination therapies that can improve disease outcomes.

Image of pills

Pipeline

Target
Indications
Mechanism
Discovery
Lead Op
IND Enabling
Clinical
NRF2 – MTAI-1025
Transcription factor
Ulcerative Colitis

Crohn’s Disease, COPD

Covalent
Discovery
Lead Op
IND Enabling
Clinical
Clinical

MTAI-1025 is an oral small molecule for ulcerative colitis (UC) designed to drive repair and durable disease remission

  • By selectively targeting NRF2, MTAI-1025 directly addresses all three components of UC—inflammation, oxidative stress and barrier repair – without broad immunosuppression
  • We are evaluating MTAI-1025 as a front-line monotherapy, and its differentiated mechanism offers the potential to be combined with other approved medicines
STAT6
Transcription factor
Th2 Mediated Diseases
Allosteric
Discovery
Lead Op
IND Enabling
Clinical
IND Enabling
Transcription factor
Th17 Mediated Diseases
Undisclosed
Discovery
Lead Op
IND Enabling
Clinical
Lead Op
Biologic replacement
Respiratory
Undisclosed
Discovery
Lead Op
IND Enabling
Clinical
Lead Op
Biologic replacement
Undisclosed
Undisclosed
Discovery
Lead Op
IND Enabling
Clinical
Discovery

Featured Publications

View All
Montai Logo

26 Landsdowne St. Cambridge, MA 02139

Partnerships partnerships@montai.com
Press press@montai.com

Careers

We are growing our team of leaders, committed to finding breakthroughs to make a difference in as many lives as possible.

View Open Positions up-right-arrow (1)

Quick Links

Legal

© 2026 Montai Therapeutics, Inc.
All rights reserved.

A Flagship Pioneering Company